Almirall S.A. Logo

Almirall S.A.

Global biopharmaceutical company specializing in medical dermatology and skin health.

ALM | MC

Overview

Corporate Details

ISIN(s):
ES0157097017
LEI:
95980020140005007996
Country:
Spain
Address:
Ronda General Mitre 151, 08022 Barcelona

Description

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 18:19
Almirall ha procedido al cierre y desembolso de su emisión de obligaciones simp…
Spanish 184.0 KB
2025-05-12 07:33
Información sobre el calendario del dividendo
Spanish 104.4 KB
2025-05-12 07:23
Información sobre dividendos
Spanish 188.2 KB
2025-05-12 07:15
Acuerdos adoptados por el Consejo de Administración
Spanish 105.9 KB
2025-05-12 07:04
Acuerdos adoptados por la Junta General de Accionistas 2025
Spanish 182.9 KB
2025-05-12 06:57
Almirall remite presentación sobre los resultados del primer trimestre de 2025 …
Spanish 1.3 MB
2025-05-12 06:51
Almirall realizará una presentación vía webcast para explicar los Resultados de…
Spanish 101.3 KB
2025-05-12 00:00
Acuerdos adoptados por la Junta General de Accionistas 2025
Spanish 182.9 KB
2025-04-09 11:58
Operaciones del contrato de liquidez durante el primer trimestre de 2025
English 187.4 KB
2025-04-01 13:17
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025 -…
Spanish 279.9 KB
2025-04-01 00:00
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025 -…
Spanish 279.9 KB
2025-03-31 17:58
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025
Spanish 141.0 KB
2025-03-31 00:00
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025
Spanish 141.0 KB
2025-03-06 07:28
Almirall anuncia el plan de transición del CFO
Spanish 72.6 KB
2025-02-24 06:43
La sociedad remite presentación sobre los resultados del ejercicio 2024
Spanish 1.3 MB

Automate Your Workflow. Get a real-time feed of all Almirall S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Almirall S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Almirall S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776
Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.